Cellink Life Sciences completes Nanoscribe acquisition
On May 31, 2021, bioconvergence company Cellink Life Sciences (Gothenburg, Sweden) finalized its acquisition of Nanoscribe (Karlsruhe, Germany), a company focusing on development of high-precision 3D printers based on two-photon polymerization (2PP) technology.
The combination of the two companies’ technologies enables Cellink to offer 2PP products for several markets, such as bioprinting, microfluidics, micro-optics, micromechanics, biomedical engineering, and integrated photonics technologies, explains Erik Gatenholm, CEO of Cellink. One example, he says, is the sample preparation steps for single-cell genomics applications.